Characterisation of sars-cov-2 genomic variation in response to molnupiravir treatment in the agile phase iia clinical trial

HIGHLIGHTS

• who: I ah Donovan-Banfield from the (UNIVERSITY) have published the paper: Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial, in the Journal: (JOURNAL) of 26/09/2022
• what: This trial evaluated molnupiravir (EIDD-2801/MK-4482), for the treatment of COVID-19 in a seamless phase I/II trial (clinicaltrials.gov registration number NCT04746183).
• how: The sequencing data indicated that transition mutations were significantly increased in viral RNA from molnupiravir treated participants at Day 3 or Day 5 compared to participants . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.